HBA1C STATUS IN TYPE II DIABETES MELLITUS WITH AND WITHOUT IRON DEFICIENCY ANAEMIA

Diabetes is an endemic global illness that is on the rise in both developed and developing countries. The American Diabetes Association has suggested glycated haemoglobin (HbA1c) as a possible substitute for fasting blood glucose in diagnosing diabetes. HbA1c is an important measure of long-term glycaemic control since it can represent the total glycaemic history of the two to three months before. In addition to providing a reliable measure of chronic hyperglycemia, HbA1c is highly correlated with the risk of long-term complications from diabetes. Elevated HbA1c has also been identified as an independent risk factor for coronary heart disease and stroke in people with or without diabetes. However, recent research has demonstrated that inadequate iron levels and glycemia contribute to high HbA1c.Therefore, decreasing circulating iron levels might be a worrying risk factor for heart attacks and strokes. The HbA1c test is an impartial biomarker for the diagnosis and outlook of diabetes since it offers valuable information with just one test. This studys results have demonstrated the significance of HbA1c in the diagnosis and prognosis of diabetic patients.

糖尿病是一种全球性流行疾病，在发达国家与发展中国家均呈持续上升态势。美国糖尿病协会（American Diabetes Association）建议将糖化血红蛋白（glycated haemoglobin, HbA1c）作为诊断糖尿病时替代空腹血糖的潜在指标。糖化血红蛋白是评估长期血糖控制状态的重要指标，因其可反映受试者2至3个月内的整体血糖暴露史。除可可靠表征慢性高血糖状态外，糖化血红蛋白还与糖尿病患者长期并发症的发生风险高度相关。无论受试者是否患有糖尿病，糖化血红蛋白水平升高均被证实为冠心病与脑卒中的独立危险因素。不过近期研究表明，铁水平不足与血糖代谢异常均可导致糖化血红蛋白水平升高。因此，降低循环铁水平或成为心肌梗死与脑卒中的令人担忧的风险因素。糖化血红蛋白检测是一种客观的生物标志物（biomarker），仅通过单次检测即可为糖尿病的诊断与预后评估提供极具价值的参考信息。本研究结果证实了糖化血红蛋白在糖尿病患者诊断及预后管理中的重要意义。